USA USA Allows the use of the first drug that helps to recover the virus
WASHINGTON: US regulators on Friday allowed the emergency use of the first that appears to help some Covid-19 patients recover more quickly, a milestone in the global search for effective therapies against the coronavirus.
The Food and Drug Administration approved the Gilead Science IV drug for hospitalized patients with severe illness, such as those experiencing respiratory problems requiring supplemental oxygen or ventilators.
President Donald trump announced the news at the White House alongside Gilead CEO Daniel O'Day and Commissioner of the Food and Drug Administration Stephen Hahn.
This was lightning fast in terms of getting something approved, Hahn said, calling the drug a major clinical advance.
the Fda actuó después de que the resultados preliminares de un estudio patrocinado por el gobierno mostraron que el medicamento, remdesivir, acortó el tiempo de recuperación en un 31%, o alrededor de cuatro días en promedio, para pacientes hospitalizados con Covid-19.
Those given the drug were able to leave the hospital in 11 days on average vs. 15 days for the comparison group. the drug may also help avert deaths, but that effect is not yet large enough for scientists to know for sure.
Critical care specialist Dr. Sameer Khanijo said he wants to see additional studies to clarify the drug's benefit.
I don't think this is a cure yet, but I think it is starting to point us in the right direction, said Khanijo of North Shore University Hospital in New York. As a society, it is good to have something to help stem the tide of this disease.
the Fda said preliminary results from the government study warranted Friday's decision, though regulators acknowledged "there is limited information known about the safety and effectiveness of using remdesivir."
the drug's side effects include potential inflammation of the liver and problems related to its infusion, which could lead to nausea, vomiting, sweating and low blood pressure. Information about dosing and potential safety issues will be provided to physicians and patients, the Fda said.
the National Institutes of Health's Dr Anthony Fauci said Wednesday the drug would become a new standard of care for severely ill Covid-19 patients. Remdesivir, which blocks an enzyme the virus uses to copy its genetic material, has not been tested on people with milder illness.
the Fda authorized the drug under its emergency powers to quickly speed the availability of experimental drugs, tests and other medical products during public health crises.
In normal times the Fda requires "substantial evidence" of a drug's safety and effectiveness, usually through one or more large, rigorously controlled patient studies. But during public health emergencies the agency can waive those standards and require only that an experimental treatment's potential benefits outweigh its risks.
Gilead has said he will donate his currently available stock of the drug and is increasing production to do more. He said the United States government would coordinate the distribution of remdesivir to the parts of the country that need it most.
No drugs are currently Fda -approved for treating the coronavirus, and remdesivir will still need formal approval.
the Fda can convert the drug's status to full approval if Gilead or other researchers provide additional data of remdesivir's safety and effectiveness.
"This is a very, very early stage so you wouldn't expect to have any sort of full approval at this point," said Cathy Burgess, an attorney specializing in Fda issues. "But obviously they want to get this out to patients as quickly as possible."
the Fda previously allowed narrow use of a malaria drug, hydroxychloroquine, for hospitalized patients who were unable to take part in ongoing studies of the medication. Trump repeatedly promoted it as a possible Covid-19 treatment, but no large high-quality studies have shown the drug works for that and it has significant safety concerns.
the Fda warned doctors late last month against prescribing the drug outside of hospital or research settings, due to risks of sometimes fatal heart side effects. the agency made the announcements after receiving new reports of injury and death with the medication, which is also used to treat lupus and rheumatoid arthritis .
Dos pequeños estudios publicados el viernes se suman a las preocupaciones sobre la hidroxicloroquina. Los pacientes en estado crítico de Covid-19 que recibieron el medicamento a base de píldoras eran propensos a problemas de ritmo cardíaco, y para muchos riesgos aumentaron cuando se combinó con un antibiótico, según the estudios.